At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for rare blood disorders, neuromuscular, and pulmonary diseases.
The clinical trials listed below are Acceleron or partner-sponsored trials, some of which are actively recruiting patients. Each trial in the list contains a link to clinicaltrials.gov, where you will find a full description and contact information.
|Luspatercept||MEDALIST Phase III*||Lower-Risk MDS|
|Luspatercept||COMMANDS Phase III*||Low or Intermediate Risk MDS|
|Luspatercept||BEYOND Phase II*||Beta-Thalassemia|
|Luspatercept||Phase II Extension||MDS|
|Luspatercept||Phase II Extension||Beta-Thalassemia|
|Luspatercept||Phase II||Anemia in Lower-Risk MDS|
|ACE-083||Phase II||Facioscapulohumeral Muscular Dystrophy|
|ACE-083||Phase II||Charcot-Marie-Tooth Disease|
|Sotatercept||PULSAR Phase II||Pulmonary Arterial Hypertension|
|Sotatercept||SPECTRA Phase II||Pulmonary Arterial Hypertension|
|Acceleron trials listed as recruiting or active on www.clinicaltrials.gov|